Investors Catching Stocks Banco Santander, S.A.(NYSE:SAN): Actinium Pharmaceuticals, Inc.(NYSE:ATNM)

0
8

Many analysts are providing their Estimated Earnings analysis for Banco Santander, S.A. and for the current quarter 0 analysts have projected that the stock could give an Average Earnings estimate of $0/share. These analysts have also projected a Low Estimate of $0/share and a High Estimate of $0/share.

Some buy side analysts are also providing their Analysis on Banco Santander, S.A., where 2 analysts have rated the stock as Strong buy, 1 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Banco Santander, S.A. might touch $6.24 high while the Average Price Target and Low price Target is $5.46 and $4.01 respectively.

Banco Santander, S.A. closed its last trading session at $3.8 with the gain of 0.53%. The Market Capitalization of the company stands at 63.73 Billion. The Company has 52-week high of $5.39 and 52-week low of $3.80. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -9.63% where SMA50 and SMA200 are -13.43% and -17.95% respectively. The Company Touched its 52-Week High on 09/20/18 and 52-Week Low on 08/14/19.

The Relative Volume of the company is 0.9 and Average Volume (3 months) is 10.85 million. The company’s P/E (price to earnings) ratio is 7.91 and Forward P/E ratio of 7.06.

The company shows its Return on Assets (ROA) value of 0%. The Return on Equity (ROE) value stands at 0%. While it’s Return on Investment (ROI) value is 6%.

While looking at the Stock’s Performance, Banco Santander, S.A. currently shows a Weekly Performance of -5.91%, where Monthly Performance is -16.04%, Quarterly performance is -17.32%, 6 Months performance is -15.49% and yearly performance percentage is -23.88%. Year to Date performance value (YTD perf) value is -14.73%. The Stock currently has a Weekly Volatility of 1.94% and Monthly Volatility of 1.58%.

Actinium Pharmaceuticals, Inc. (ATNM) will report its next earnings on Aug 15 AMC. The company reported the earnings of $-0.03/Share in the last quarter where the estimated EPS by analysts was $-0.04/share. The difference between the expected and actual EPS was $0.01/share, which represents an Earnings surprise of 25%.

Many analysts are providing their Estimated Earnings analysis for Actinium Pharmaceuticals, Inc. and for the current quarter 3 analysts have projected that the stock could give an Average Earnings estimate of $-0.04/share. These analysts have also projected a Low Estimate of $-0.05/share and a High Estimate of $-0.03/share.

Some buy side analysts are also providing their Analysis on Actinium Pharmaceuticals, Inc., where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Actinium Pharmaceuticals, Inc. might touch $4 high while the Average Price Target and Low price Target is $2.75 and $1.5 respectively.

Actinium Pharmaceuticals, Inc. closed its last trading session at $0.22 with the loss of -4.07%. The Market Capitalization of the company stands at 33.07 Million. The Company has 52-week high of $0.87 and 52-week low of $0.20. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -10.34% where SMA50 and SMA200 are -13.81% and -49.17% respectively. The Company Touched its 52-Week High on 09/26/18 and 52-Week Low on 08/05/19.

The Relative Volume of the company is 0.5 and Average Volume (3 months) is 1.08 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -140.7%. The Return on Equity (ROE) value stands at -213.7%. While it’s Return on Investment (ROI) value is 0%.

While looking at the Stock’s Performance, Actinium Pharmaceuticals, Inc. currently shows a Weekly Performance of -5.28%, where Monthly Performance is -8.81%, Quarterly performance is -22.19%, 6 Months performance is -60.38% and yearly performance percentage is -66.13%. Year to Date performance value (YTD perf) value is -45.74%. The Stock currently has a Weekly Volatility of 6.85% and Monthly Volatility of 7.98%.

SHARE